Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025484) USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025484 International Application No.: PCT/EP2018/070856
Publication Date: 07.02.2019 International Filing Date: 01.08.2018
IPC:
A61K 31/4709 (2006.01) ,A61K 35/17 (2015.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4709
Non-condensed quinolines containing further heterocyclic rings
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG [DE/DE]; Sanderring 2 97070 Würzburg, DE
Inventors:
HUDECEK, Michael; DE
JETANI, Hardikkumar; DE
Agent:
HOFFMANN EITLE PATENT- UND RECHTSANWÄLTE PARTMBB; Arabellastraße 30 81925 Munich, DE
Priority Data:
17184277.601.08.2017EP
Title (EN) USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA
(FR) UTILISATION DE LYMPHOCYTES T MODIFIÉS PAR CAR POUR FLT3 ET D'INHIBITEURS DE FLT3 POUR TRAITER LA LEUCÉMIE MYÉLOÏDE AIGUË
Abstract:
(EN) The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.
(FR) L'invention concerne de manière générale le traitement du cancer avec des agents ciblant le FLT3 et des inhibiteurs de kinase. En particulier, l'invention concerne l'immunothérapie adoptive de la leucémie myéloïde aiguë (LMA) avec des lymphocytes T modifiés par un récepteur d'antigène chimère (CAR) spécifiques pour la tyrosine kinase de type FMS (FLT3) en combinaison avec des inhibiteurs de FLT3.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)